CCAAT/Enhancer Binding Protein β Is Dispensable for Development of Lung Adenocarcinoma

• Yi Cai ,

  Contributed equally to this work with: Yi Cai, Ayako Hirata

  Affiliation Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Ayako Hirata ,

  Contributed equally to this work with: Yi Cai, Ayako Hirata

  Affiliations Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America, Department of Transfusion Medicine & Cell Therapy, Kyoto University Hospital, Kyoto, Japan

  ⨯
• Sohei Nakayama,

  Affiliation Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Paul A. VanderLaan,

  Affiliation Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Elena Levantini,

  Affiliations Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America, Institute of Biomedical Technologies, National Research Council (CNR), Pisa, Italy

  ⨯
• Mihoko Yamamoto,

  Affiliation Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Hideyo Hirai,

  Affiliation Department of Transfusion Medicine & Cell Therapy, Kyoto University Hospital, Kyoto, Japan

  ⨯
• Kwok-Kin Wong,

  Affiliation Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America

  ⨯
• Daniel B. Costa,

  Affiliation Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Hideo Watanabe ,

  * E-mail: hideo_watanabe@dfci.harvard.edu (HW); skobayas@bidmc.harvard.edu (SSK)

  ¶‡ HY and SSK are joint senior authors on this work.

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America

  ⨯
• Susumu S. Kobayashi

  * E-mail: hideo_watanabe@dfci.harvard.edu (HW); skobayas@bidmc.harvard.edu (SSK)

  ¶‡ HY and SSK are joint senior authors on this work.

  Affiliations Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America, Harvard Stem Cell Institute, Cambridge, Massachusetts, United States of America

  ⨯